Vaxcell Bio Therapeutics
KOSDAQ:323990
Cash Flow Statement
Cash Flow Statement
Vaxcell Bio Therapeutics
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||||||||||
| Net Income |
(1 992)
|
(3 984)
|
(4 760)
|
(4 059)
|
(4 482)
|
(4 763)
|
(5 672)
|
(5 667)
|
(6 039)
|
(6 825)
|
(7 383)
|
(8 554)
|
(9 689)
|
(10 274)
|
(10 482)
|
(10 432)
|
(10 027)
|
(10 624)
|
(10 789)
|
(12 166)
|
(12 440)
|
|
| Depreciation & Amortization |
256
|
185
|
235
|
209
|
213
|
257
|
283
|
295
|
304
|
311
|
317
|
323
|
326
|
400
|
478
|
834
|
1 068
|
1 466
|
1 753
|
1 919
|
1 976
|
|
| Stock-Based Compensation |
33
|
132
|
62
|
64
|
59
|
47
|
27
|
57
|
11
|
38
|
91
|
131
|
176
|
237
|
246
|
255
|
327
|
209
|
171
|
178
|
163
|
|
| Other Non-Cash Items |
(2 389)
|
560
|
660
|
416
|
384
|
270
|
218
|
139
|
122
|
291
|
214
|
290
|
290
|
(127)
|
(718)
|
(1 259)
|
(1 566)
|
(1 449)
|
(1 307)
|
(622)
|
(811)
|
|
| Cash Taxes Paid |
(5)
|
(8)
|
(6)
|
(1)
|
(5)
|
5
|
5
|
(1)
|
(0)
|
60
|
67
|
19
|
35
|
53
|
56
|
14
|
82
|
141
|
128
|
82
|
(4)
|
|
| Change in Working Capital |
(500)
|
(65)
|
(706)
|
(540)
|
(1 192)
|
(427)
|
(202)
|
(515)
|
164
|
178
|
478
|
908
|
471
|
578
|
83
|
302
|
1 221
|
(92)
|
(316)
|
(353)
|
(1 096)
|
|
| Cash from Operating Activities |
(4 625)
N/A
|
(3 303)
+29%
|
(4 571)
-38%
|
(3 974)
+13%
|
(5 077)
-28%
|
(4 662)
+8%
|
(5 373)
-15%
|
(5 749)
-7%
|
(5 449)
+5%
|
(6 045)
-11%
|
(6 373)
-5%
|
(7 033)
-10%
|
(8 603)
-22%
|
(9 423)
-10%
|
(10 639)
-13%
|
(10 555)
+1%
|
(9 304)
+12%
|
(10 699)
-15%
|
(10 659)
+0%
|
(11 222)
-5%
|
(12 371)
-10%
|
|
| Investing Cash Flow | ||||||||||||||||||||||
| Capital Expenditures |
(493)
|
(32)
|
(232)
|
(353)
|
(562)
|
(2 228)
|
(2 129)
|
(2 015)
|
(1 925)
|
(290)
|
(223)
|
(224)
|
(101)
|
(199)
|
(963)
|
(2 314)
|
(3 571)
|
(4 065)
|
(3 286)
|
(2 691)
|
(4 917)
|
|
| Other Items |
(3 983)
|
(20 017)
|
(18 017)
|
(18 019)
|
(17 319)
|
(1 009)
|
(3 004)
|
2 011
|
1 311
|
4 624
|
7 621
|
4 610
|
7 288
|
(51 588)
|
(58 044)
|
(52 912)
|
(53 428)
|
14 388
|
17 031
|
16 118
|
16 966
|
|
| Cash from Investing Activities |
(4 476)
N/A
|
(20 049)
-348%
|
(18 249)
+9%
|
(18 372)
-1%
|
(17 881)
+3%
|
(3 237)
+82%
|
(5 133)
-59%
|
(4)
+100%
|
(614)
-13 937%
|
4 333
N/A
|
7 398
+71%
|
4 386
-41%
|
7 187
+64%
|
(51 787)
N/A
|
(59 007)
-14%
|
(55 226)
+6%
|
(56 999)
-3%
|
10 322
N/A
|
13 745
+33%
|
13 427
-2%
|
12 049
-10%
|
|
| Financing Cash Flow | ||||||||||||||||||||||
| Net Issuance of Common Stock |
31 731
|
29 366
|
29 964
|
29 964
|
(468)
|
597
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
71 257
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
(1 284)
|
(186)
|
(235)
|
(198)
|
863
|
(206)
|
(209)
|
(209)
|
(207)
|
(208)
|
(191)
|
(176)
|
(161)
|
(217)
|
(263)
|
(492)
|
(711)
|
(849)
|
(983)
|
(1 318)
|
(1 143)
|
|
| Other |
0
|
0
|
(87)
|
(87)
|
(87)
|
(87)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1 174)
|
0
|
(1 174)
|
(1 174)
|
0
|
0
|
(1)
|
(1)
|
|
| Cash from Financing Activities |
30 448
N/A
|
29 180
-4%
|
29 642
+2%
|
29 679
+0%
|
309
-99%
|
305
-1%
|
(209)
N/A
|
(209)
0%
|
(207)
+1%
|
(208)
0%
|
(191)
+8%
|
(176)
+8%
|
(161)
+8%
|
69 866
N/A
|
69 820
0%
|
69 591
0%
|
69 372
0%
|
(849)
N/A
|
(983)
-16%
|
(1 319)
-34%
|
(1 143)
+13%
|
|
| Change in Cash | ||||||||||||||||||||||
| Net Change in Cash |
21 346
N/A
|
5 828
-73%
|
6 822
+17%
|
7 333
+7%
|
(22 649)
N/A
|
(7 594)
+66%
|
(10 716)
-41%
|
(5 962)
+44%
|
(6 270)
-5%
|
(1 919)
+69%
|
833
N/A
|
(2 823)
N/A
|
(1 577)
+44%
|
8 657
N/A
|
173
-98%
|
3 810
+2 098%
|
3 069
-19%
|
(1 225)
N/A
|
2 104
N/A
|
886
-58%
|
(1 465)
N/A
|
|
| Free Cash Flow | ||||||||||||||||||||||
| Free Cash Flow |
(5 118)
N/A
|
(3 335)
+35%
|
(4 803)
-44%
|
(4 327)
+10%
|
(5 639)
-30%
|
(6 890)
-22%
|
(7 503)
-9%
|
(7 764)
-3%
|
(7 373)
+5%
|
(6 335)
+14%
|
(6 596)
-4%
|
(7 257)
-10%
|
(8 704)
-20%
|
(9 621)
-11%
|
(11 602)
-21%
|
(12 869)
-11%
|
(12 876)
0%
|
(14 764)
-15%
|
(13 944)
+6%
|
(13 913)
+0%
|
(17 288)
-24%
|
|